Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Pulls The Plug On Next-Gen Antipsychotic

This article was originally published in The Pink Sheet Daily

Executive Summary

With one Phase III trial failed and a second halted for futility, Eli Lilly calls it quits on pomaglumetad methionil, a compound the pharma had hoped would succeed blockbuster antipsychotic Zyprexa, marking the end of the road for a pioneering compound in the effort to drug metabotropic glutamate receptors (mGluRs), a promising class for CNS therapies.

You may also be interested in...



Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure

Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.

Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure

Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.

Cruel Summer: High-Profile Trial Failures Dominate R&D News Flow

As the summer of 2012 wears on, an outpouring of negative clinical trial news for high-profile new drug candidates has made the season more a time of doldrums than of fun in the sun for big pharma.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074577

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel